Biotech IPO window is opening but big pharma M&A still sets the pace, top bankers tell CNBC
分析失败
Biopharma dealmaking is driven by pressure to top up drug pipelines ahead of major patent expirations later this decade.
LISA · 延伸对话
与 Lisa 深入探讨这篇报告
基于本报告上下文的延伸分析